XTuit Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From XTuit Pharmaceuticals Inc.
With a new CEO taking the reins in September and a candidate entering the clinic for Parkinson’s disease, Lundbeck has opportunities for refreshment, both in the pipeline and the boardroom. But with generic competition battering down the company’s financial outlook, it may not be enough to bring the market along for the ride.
Deborah Dunsire’s appointment to lead Lundbeck tops this week’s list of new hires; Astellas, Orchard Therapeutics, Voyager Therapeutics, iTeos Therapeutics, Cevec Pharmaceuticals, Sangamo Therapeutics, Cedilla Therapeutics, Tilos Therepautics and Neos Therapeutics have also appointed new executives and directors.
Scrip talked to five female CEOs about the barriers in biopharma that prevent more women from reaching the top leadership ranks and their thoughts on what industry can do to improve gender diversity.
Despite the recent volatility in the stock market, experts and industry insiders at the BIO CEO & Investor conference in New York said biotech remains a leading area to invest, predicting continued VC investment and more M&A ahead.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing